Anebulo Pharmaceuticals/$ANEB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies.
Ticker
$ANEB
Sector
Primary listing
Employees
-
Headquarters
Website
ANEB Metrics
BasicAdvanced
$95M
-
-$0.25
-0.89
-
Price and volume
Market cap
$95M
Beta
-0.89
52-week high
$3.42
52-week low
$0.80
Average daily volume
88K
Financial strength
Current ratio
24.529
Quick ratio
23.993
Interest coverage (TTM)
-24.14%
Profitability
Management effectiveness
Return on assets (TTM)
-71.09%
Return on equity (TTM)
-109.69%
Valuation
Price to book
8.18
Price to tangible book (TTM)
8.18
Price to free cash flow (TTM)
-12.357
Free cash flow yield (TTM)
-8.09%
Free cash flow per share (TTM)
-0.188
Growth
Earnings per share change (TTM)
-21.01%
3-year earnings per share growth (CAGR)
-4.98%
What the Analysts think about ANEB
Majority rating from 3 analysts.
ANEB News
AllArticlesVideos
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
Business Wire2 weeks ago
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
Business Wire3 weeks ago
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Anebulo Pharmaceuticals stock?
Anebulo Pharmaceuticals (ANEB) has a market cap of $95M as of October 13, 2025.
What is the P/E ratio for Anebulo Pharmaceuticals stock?
The price to earnings (P/E) ratio for Anebulo Pharmaceuticals (ANEB) stock is 0 as of October 13, 2025.
Does Anebulo Pharmaceuticals stock pay dividends?
No, Anebulo Pharmaceuticals (ANEB) stock does not pay dividends to its shareholders as of October 13, 2025.
When is the next Anebulo Pharmaceuticals dividend payment date?
Anebulo Pharmaceuticals (ANEB) stock does not pay dividends to its shareholders.
What is the beta indicator for Anebulo Pharmaceuticals?
Anebulo Pharmaceuticals (ANEB) has a beta rating of -0.89. This means that it has an inverse relation to market volatility.